Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Other(1)

Detailed Status

Completed3
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

recruiting233%
completed350%
unknown117%

Recent Activity

2 active trials
Showing 5 of 6
completedphase_2

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

NCT05382312
recruitingphase_2

PanACEA - STEP2C -01

NCT05807399
recruitingphase_2

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

NCT06114628
unknownphase_2

BTZ-043 Dose Evaluation in Combination and Selection

NCT05926466
completedphase_1

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

NCT04044001
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05382312Phase 2

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

Completed
NCT05807399Phase 2

PanACEA - STEP2C -01

Recruiting
NCT06114628Phase 2

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting
NCT05926466Phase 2

BTZ-043 Dose Evaluation in Combination and Selection

Unknown
NCT04044001Phase 1

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

Completed
NCT03590600Phase 1

A Single Ascending Dose Study of BTZ043

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6